By: Darcy Burbage, MSN, RN, AOCN, CBCN From: oncologynurseadvisor.com Breast cancer is the most commonly diagnosed cancer in women, with incidence rates of invasive cancer upwards of 200,000 new cases per year plus an estimated additional 63,000 cases of in situ breast cancer.1 Because of this, more than 3.5 million breast cancer survivors are alive today either with a history …
Does Discipline Make A Difference In Getting Breast Cancer?
View PostJefferson researcher discovers a population of bone cells that subdues cancer
Source: jefferson.edu From: news-medical.net In breast cancer, there are cases of women and men whose cancer returns in their bones 20-30 years after they were treated for their primary disease and thought they were cancer-free. This phenomenon always puzzled Jefferson researcher Karen Bussard, PhD. How is it possible that breast cancer cells from a primary tumor are able to reach …
6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return
By: Peter Thorley, University of Warwick From: medicalxpress.com A new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning. The majority of clinical trials in cancer assess either new treatments or additional treatments to the current standard …
Breast Cancer Recurrence Not Linked To Anesthesia Administration Mode
By: Jenna Bassett, PhD From: clinicaloncology.com “The leading cause of death after cancer surgery is the recurrence of cancer,” said senior study author Jin-Tae Kim, MD, PhD, of the Department of Anesthesiology and Pain Medicine at Seoul National University Hospital, South Korea. “If there is a difference in cancer recurrence rate according to the type of anesthesia used, even a …
ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1
From: physiciansweekly.com Latest analysis from IMpassion trial confirms need for testing One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies, and that message came through loud and clear during an oral abstract session devoted to treatment of …
FDA Approvals in Non-Hodgkin Lymphoma, Breast Cancer, GVHD, and Mesothelioma
By: Kristi Rosa From: onclive.com FDA approvals in non-Hodgkin lymphoma, breast cancer, graft-versus-host disease, and mesothelioma, and a breakthrough therapy designation in cervical cancer. The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma. The approval was primarily based on findings from the phase III AUGMENT …
Breast MRI may be too sensitive for some for annual cancer screening
By: Amy Norton, HealthDay News From: upi.com Researchers say that while MRI picks up more than a mammogram, it also can lead to false positives and unneeded biopsies. Breast MRI screening is a good way to detect small tumors, but it’s unclear how much it benefits women with a history of breast cancer, a new study finds. Right now, experts …
Physics could answer questions about breast cancer spreading to bones
IUPUI researchers hope to learn how cancer cells generate enough force to move from a tumor site through the body and then settle into bones To fully understand why breast cancer spreads, or metastasizes, you must also consider the how. That’s what researchers in a biophysics and imaging laboratory in the School of Science at IUPUI did as they studied …
Adding targeted therapy to treatment extends lives of those with metastatic breast cancer
Source: UCLA Jonsson Comprehensive Cancer Center From: eurekalert.org A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy. Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the …